TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30643069

Group type: EXPERIMENTAL
Intervention: Manipulation combined with biofeedback electrical stimulation treatment for 30 days
Number of subjects: 72

Group type: COMPARATOR
Intervention: Manipulation therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Electrical stimulation biofeedback therapy
Number of subjects: 72
Study: 27396247

Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block added to infraclavicular brachial plexus block
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (infraclavicular brachial plexus block only)
Number of subjects: 11
Study: 24972190

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg tid for a mean of 36.6 days
Number of subjects: 11
Study: 22783708

Group type: EXPERIMENTAL
Intervention: LMA-Supreme
Number of subjects: 150

Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 150

Group type: COMPARATOR
Intervention: LMA-ProSeal
Number of subjects: 150
Study: 19563466

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.03% ointment
Number of subjects: 479

Group type: COMPARATOR
Intervention: Fluticasone 0.005% ointment
Number of subjects: 479
Study: 17634259

Group type: EXPERIMENTAL
Intervention: CHO+PRO (0.3 g x kg(‐1) protein hydrolysate)
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO (0.3 g x kg(‐1) carbohydrate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: CHO+PRO
Number of subjects: 7

Group type: COMPARATOR
Intervention: CHO
Number of subjects: 7
Study: 16075773

Group type: EXPERIMENTAL
Intervention: Print-based intervention
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Print-plus-telephone mediated intervention
Number of subjects: 66
Study: 11437018

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group treatment for depression
Number of subjects: 151

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 151
Study: 9510453

Group type: EXPERIMENTAL
Intervention: Discontinuation of CPAP
Number of subjects: 88

Group type: COMPARATOR
Intervention: Continuation of CPAP
Number of subjects: 88
Study: 8290177

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 1.25 mg conjugated equine estrogen
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cyclic medroxyprogesterone acetate (progestin) added to estrogen
Number of subjects: 103
Study: 3678121

Group type: EXPERIMENTAL
Intervention: Automatic sampling shield
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control feeds
Number of subjects: 13
Study: 30465382

Group type: EXPERIMENTAL
Intervention: Proximal AVF (Group B)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Distal AVF (Group A)
Number of subjects: 230
Study: 28095544

Group type: EXPERIMENTAL
Intervention: Same-day sequential Q-switched Nd:YAG laser and 1565 nm non-ablative fractional laser (SST)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Fractional non-ablative laser (NAFL) treatment only
Number of subjects: 17
Study: 24947625

Group type: EXPERIMENTAL
Intervention: LRYGB with closing of mesenteric defects using hernia clips
Number of subjects: 500

Group type: COMPARATOR
Intervention: LRYGB without closing the mesenteric defects
Number of subjects: 500
Study: 24034101

Group type: EXPERIMENTAL
Intervention: Stenting of iliac vein after catheter-directed thrombolysis (CDT)
Number of subjects: 74

Group type: COMPARATOR
Intervention: No stenting (control group)
Number of subjects: 74
Study: 22047542

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFO)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 400
Study: 19392908

Group type: EXPERIMENTAL
Intervention: Extended Cognitive Behavioral Therapy (E-CBT)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Extended Nicotine Replacement Therapy (E-NRT)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 402

Group type: COMPARATOR
Intervention: E-CBT plus E-NRT (E-combined)
Number of subjects: 402
Study: 17047492

Group type: EXPERIMENTAL
Intervention: efavirenz
Number of subjects: 340

Group type: EXPERIMENTAL
Intervention: efavirenz without nelfinavir
Number of subjects: 340
Study: 12737857

Group type: EXPERIMENTAL
Intervention: High dietary fibre intake (highest quintile)
Number of subjects: 39562

Group type: EXPERIMENTAL
Intervention: Fibre from grains and cereals
Number of subjects: 39562

Group type: EXPERIMENTAL
Intervention: Fibre from fruits
Number of subjects: 39562

Group type: EXPERIMENTAL
Intervention: Advanced and non-advanced adenoma
Number of subjects: 39562

Group type: EXPERIMENTAL
Intervention: Rectal adenoma
Number of subjects: 39562
Study: 11876893

Group type: EXPERIMENTAL
Intervention: Irradiated drug-containing porcine-cornea (ofloxacin, acetyl cysteine, reduced glutathione)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Routine program
Number of subjects: 55
Study: 9292758

Group type: EXPERIMENTAL
Intervention: Black tea (six mugs daily)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (water, caffeine, milk and sugar)
Number of subjects: 65
Study: 8378047

Group type: EXPERIMENTAL
Intervention: Light-cured materials (Vitrebond)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Light-cured materials (Prisma VLC Dycal)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemically cured materials (Ketac Fil)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemically cured materials (Dycal)
Number of subjects: 60
Study: 6367413

Group type: EXPERIMENTAL
Intervention: verapamil (0.2 mg/kg total by bolus and by 10-minute infusion)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (saline solution)
Number of subjects: 16
Study: 31071658

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 50
Study: 29521039

Group type: EXPERIMENTAL
Intervention: Silicone Ahmed® valves
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polypropylene Ahmed® valves
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 27367585

Group type: EXPERIMENTAL
Intervention: Supplementation with 10 mg Lutein, 2 mg Zeaxanthin, and 10 mg Meso-zeaxanthin for 12 months
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 105
Study: 24440210

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine with anti-helminthic treatment
Number of subjects: 252

Group type: COMPARATOR
Intervention: Liquid formulation of Ty21a vaccine without anti-helminthic treatment
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Liquid formulation of Ty21a vaccine
Number of subjects: 252
Study: 22158730

Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet (>40% of energy from protein and 30% of energy from fat)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard-protein (SP) diet (<15% of energy from protein and 30% of energy from fat)
Number of subjects: 57
Study: 20345508

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 18046665

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16393283

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 116

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 116
Study: 14996676

Group type: EXPERIMENTAL
Intervention: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus low-dose ribavirin (800 mg/d)
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 48 weeks plus low-dose ribavirin (800 mg/d)
Number of subjects: 1311

Group type: COMPARATOR
Intervention: Peginterferon-alpha2a, 180 microg/wk for 24 weeks plus standard-dose ribavirin (1000 or 1200 mg/d)
Number of subjects: 1311
Study: 10969302

Group type: EXPERIMENTAL
Intervention: Circle absorber system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NasOral system
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resuscitation bags (disk type and duck-bill type with one-way exhalation valves)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Resuscitation bags (duck-bill bags without exhalation valves)
Number of subjects: 20
Study: 8971958

Group type: EXPERIMENTAL
Intervention: 1 microgram of 1,25(OH)2D3 administered orally for 7 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 0.5 microgram of 1,25(OH)2D3 administered orally for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 12
Study: 1737537

Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle cream (control)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical 0.075% capsaicin cream (open-label study)
Number of subjects: 22
Study: 6393805

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (2 g intramuscular injections at 6-hr intervals)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (normal saline injections)
Number of subjects: 100
Study: 31596461

Group type: EXPERIMENTAL
Intervention: Gabapentin (preoperative 15 mg/kg, postoperative 7.5 mg/kg two times per day for three days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30076807

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and midazolam
Number of subjects: 88

Group type: COMPARATOR
Intervention: Propofol and midazolam
Number of subjects: 88
Study: 28212463

Group type: EXPERIMENTAL
Intervention: AZD5423 (inhaled selective glucocorticoid receptor modulator)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Reference glucocorticoid receptor agonist (double the approved dose)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: AZD5423 and reference control
Number of subjects: 353
Study: 25974071

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Number of subjects: 695

Group type: COMPARATOR
Intervention: Usual prenatal care (control group)
Number of subjects: 695
Study: 23972320

Group type: EXPERIMENTAL
Intervention: Combination therapy (montelukast 4 mg and levocetirizine 2.5 mg/5 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Levocetirizine 2.5 mg/5 ml
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 21711959

Group type: EXPERIMENTAL
Intervention: Montelukast alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levocetirizine alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desloratadine alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast and Levocetirizine combination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montelukast and Antihistamine combinations
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 19395184

Group type: EXPERIMENTAL
Intervention: RT plus 6 months of HT
Number of subjects: 206

Group type: COMPARATOR
Intervention: RT
Number of subjects: 206
Study: 17000361

Group type: EXPERIMENTAL
Intervention: Exercise echocardiography (EE)
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Resting mitral regurgitation (MR)
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: Resting MR, peak double product, peak left ventricular ejection fraction, MR worsening
Number of subjects: 1916

Group type: EXPERIMENTAL
Intervention: MR worsening
Number of subjects: 1916
Study: 15023617

Group type: EXPERIMENTAL
Intervention: High olive oil diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: High carbohydrate low olive oil diet
Number of subjects: 0
Study: 11072942

Group type: EXPERIMENTAL
Intervention: Topical sodium butyrate (80 mmol/L, 80 mL/24 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline enemas
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Topical sodium butyrate (after switching from saline)
Number of subjects: 20
Study: 8649634

Group type: EXPERIMENTAL
Intervention: Intracutaneous vaccination (10 micrograms once a week for 12 weeks)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Intramuscular vaccination (40 micrograms at 0, 1, and 3 months)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Intracutaneous vaccination
Number of subjects: 25
Study: 1534476

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (0.1 mg of 17 beta-estradiol via dermal patches for days 1 to 21 and oral medroxyprogesterone acetate for days 11 to 21 of a 28-day cycle)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Transdermal estrogen
Number of subjects: 75
Study: 6749228

Group type: EXPERIMENTAL
Intervention: High levels of life stress and social isolation
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Low levels of life stress and social isolation
Number of subjects: 2320

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 2320

Group type: EXPERIMENTAL
Intervention: Total deaths and sudden cardiac deaths
Number of subjects: 2320
Study: 30429078

Group type: EXPERIMENTAL
Intervention: REFLEX intervention
Number of subjects: 121

Group type: COMPARATOR
Intervention: Active control condition (group‐wise simplified cognitive remediation training)
Number of subjects: 121
Study: 29869078

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block along with systemic analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Systemic analgesia only (Control group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transversus abdominis plane (USG-TAP) block
Number of subjects: 60
Study: 26838580

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation (AF)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Conventional fractionation (CF)
Number of subjects: 108
Study: 24271137

Group type: EXPERIMENTAL
Intervention: Evacetrapib 1200 mg daily for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg for 1 day (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo for 10 days
Number of subjects: 0
Study: 22752605

Group type: EXPERIMENTAL
Intervention: Pseudomonas aeruginosa
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Nocardia spp.
Number of subjects: 488

Group type: EXPERIMENTAL
Intervention: Staphylococcus spp.
Number of subjects: 488
Study: 20674895

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal aspiration and sclerotherapy with 98% ethanol
Number of subjects: 33
Study: 17389552

Group type: EXPERIMENTAL
Intervention: PTC124 single-dose administration (3 to 200 mg/kg, specifically 50 mg/kg for pharmacokinetics)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PTC124 multiple-dose administration (10 to 50 mg/kg/dose twice per day for up to 14 days)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PTC124 pharmacokinetics
Number of subjects: 62
Study: 15786487

Group type: EXPERIMENTAL
Intervention: Escitalopram (initiated at 10 mg/day, increased to a maximum of 20 mg/day)
Number of subjects: 5453
Study: 11235922

Group type: EXPERIMENTAL
Intervention: Ziprasidone i.m. 10 mg
Number of subjects: 117

Group type: COMPARATOR
Intervention: Ziprasidone i.m. 2 mg
Number of subjects: 117
Study: 9493770

Group type: EXPERIMENTAL
Intervention: Transversus abdominis EMG onset in LBP subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rectus abdominis, erector spinae, and oblique abdominal muscles EMG onset in LBP subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study: 7921531

Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (2.5 to 15 mg, i.v. or oral)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (5 mg i.v.)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (10 mg oral)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (7.5 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 16 alpha-gitoxin (various doses)
Number of subjects: 52
Study: 3048090

Group type: EXPERIMENTAL
Intervention: Cefixime 400 mg once daily for 10 days
Number of subjects: 565

Group type: COMPARATOR
Intervention: Amoxicillin 250 mg three times daily for 10 days
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 565

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 565
Study: 29193126

Group type: EXPERIMENTAL
Intervention: 10 mg azeloprazole sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg azeloprazole sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg azeloprazole sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg rabeprazole sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 mg rabeprazole sodium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 mg azeloprazole sodium (before a meal)
Number of subjects: 0
Study: 27921162

Group type: EXPERIMENTAL
Intervention: Ajust™ SIMS
Number of subjects: 58

Group type: COMPARATOR
Intervention: Align™ transobturator tape sling
Number of subjects: 58
Study: 26445155

Group type: EXPERIMENTAL
Intervention: 14-week physical education and games course (n = 49)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Comparison group (n = 34)
Number of subjects: 83
Study: 23160722

Group type: EXPERIMENTAL
Intervention: Yogurt drink (doogh) fortified with 500 IU vitamin D/250 mL for 12 weeks
Number of subjects: 140
Study: 21245751

Group type: EXPERIMENTAL
Intervention: Mitral valve repair
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mitral valve replacement (MVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical revascularization alone
Number of subjects: 0
Study: 18308250

Group type: EXPERIMENTAL
Intervention: Rapid treatment (COJEC regimen: cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Standard treatment (OPEC and OJEC regimens: vincristine, cisplatin, etoposide, cyclophosphamide)
Number of subjects: 262
Study: 16219350

Group type: EXPERIMENTAL
Intervention: Combination of recombinant erythropoietin (r‐EPO) and thalidomide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thalidomide alone (for responders of group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: r‐EPO alone (for responders of group B)
Number of subjects: 30
Study: 12650658

Group type: COMPARATOR
Intervention: Metronidazole treatment
Number of subjects: 0
Study: 10750335

Group type: EXPERIMENTAL
Intervention: H 50 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: H 100 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9421123

Group type: EXPERIMENTAL
Intervention: OME/AMO (Omeprazole 2 x 40 mg and Amoxicillin 4 x 500 mg)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: OME/AMO/BSC (Omeprazole 2 x 40 mg, Amoxicillin 4 x 500 mg, and Bismuth Subcitrate 4 x 120 mg)
Number of subjects: 167
Study: 8305999

Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: No mammography screening (unscreened)
Number of subjects: 0
Study: 3315825

Group type: EXPERIMENTAL
Intervention: Propranolol (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol (n = 5)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 6)
Number of subjects: 19
Study: 31441525

Group type: EXPERIMENTAL
Intervention: WeChat health education programme (3 months)
Number of subjects: 120
Study: 27715322

Group type: EXPERIMENTAL
Intervention: Exercise intervention using a pedal exerciser
Number of subjects: 58

Group type: COMPARATOR
Intervention: Standard medical and pharmacological care (Control)
Number of subjects: 58
Study: 26312597

Group type: EXPERIMENTAL
Intervention: Teriparatide therapy (20 µg twice daily) for 1 week
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard treatment (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Teriparatide therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Teriparatide therapy and Standard treatment (control)
Number of subjects: 16
Study: 23017610

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) program, three sessions a week for 20 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (health and cultural information classes for 20 weeks)
Number of subjects: 55
Study: 21498114

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO(3)) ingestion (0.3 g kg(‐1) body mass)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 7
Study: 19140238

Group type: EXPERIMENTAL
Intervention: 5 mg glyceryl trinitrate
Number of subjects: 74

Group type: COMPARATOR
Intervention: 100 mg vitamin C (placebo)
Number of subjects: 74
Study: 17711595

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings (ECS) worn daily on the DVT-affected leg for 2 years
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo (inactive) stockings worn daily on the DVT-affected leg for 2 years
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: ECS
Number of subjects: 800
Study: 15154856

Group type: EXPERIMENTAL
Intervention: Intramuscular infusion of a combination of bradykinin, serotonin, histamine, and prostaglandin E2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 12464382

Group type: EXPERIMENTAL
Intervention: Separate mailout (two letters)
Number of subjects: 2393

Group type: COMPARATOR
Intervention: Joint mailout (one letter)
Number of subjects: 2393
Study: 9821565

Group type: EXPERIMENTAL
Intervention: 0.5 mol/L sodium lactate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (3% sodium chloride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 0
Study: 7545257

Group type: EXPERIMENTAL
Intervention: Hyperthermochemoradiotherapy (HCR)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chemoradiotherapy (CR)
Number of subjects: 66
Study: 2506844

Group type: EXPERIMENTAL
Intervention: Centrophenoxine (CPH) 2 g/day for 8 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo tablets for 8 weeks
Number of subjects: 50
Study: 823433

Group type: EXPERIMENTAL
Intervention: 3.5% amino acid solution
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5% glucose
Number of subjects: 10